Table 2: PET results for desmoid patients ( ) treated with imatinib.

Patient no.Age (years)Tumor localizationImatinib treatment duration (months)Average SUV (initial)Average SUV (follow-up)SUV change (%)Response according to RECISTPFS (months)

164Chest62.9022.538 PD6
270Pelvis53.1713.364 SD5
331Retroperitoneal744.2333.294 PR74+
442Mesenterium43.0232.793 PD4
522Chest153.3201.711 SD15
635Supraclavicular62.1151.851 SD6
727Upper limb583.1122.428 SD58+
870Buttock602.7852.632 SD60+
938Pelvis492.3761.735 SD49+
1068Shoulder122.0981.458 PD12
1143Upper limb82.1001.600 PD8
1248Pelvis92.9002.800 SD9+
1340Pelvis263.5002.100 PR26+
1447Upper limb282.3001.800 PR28+
1554Chest15.2293.100 SD22
1630Pelvis183.0742.400 SD18+
1724Mesenterium1711.5731.981 SD16+
1848Chest32.0591.975 PD3
1941Buttock152.0002.100 PR15+
2070Parascapular132.9002.114 PR13+
2139Fossa ischiorectalis52.4922.100 SD5+
2275Mesenterium14.037n.e.n.e.SD1+

SUV: standardized uptake value; RECIST: Response Evaluation Criteria in Solid Tumors; PFS: progression-free survival; PR: partial response; PD: progressive disease; SD: stable disease; n.e.: not evaluable; +: patient is still progression-free at the time of data collection and continues treatment with imatinib.